The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma

Daniel Weissinger\textsuperscript{1,2}, Katrin E Tagscherer\textsuperscript{1,2}, Stephan Macher-Göppinger\textsuperscript{1,2}, Axel Haferkamp\textsuperscript{3}, Nina Wagener\textsuperscript{4,5} and Wilfried Roth\textsuperscript{1,2}\textsuperscript{*}

Abstract

Background: Overexpression of Decoy Receptor 3 (DcR3), a soluble member of the tumor necrosis factor receptor superfamily, is a common event in several types of cancer. In renal cell carcinoma (RCC), DcR3 overexpression is associated with lymph node and distant metastasis as well as a poor prognosis. However, the functional role and regulation of DcR3 expression in RCC is so far unknown.

Methods: Modulation of DcR3 expression by siRNA and ectopic gene expression, respectively, was performed in ACHN and 769-P RCC cell lines. Functional effects of a modulated DcR3 expression were analyzed with regard to migration, invasion, adhesion, clonogenicity, and proliferation. Furthermore, quantitative RT-PCR and immunoblot analyses were performed to evaluate the expression of downstream mediators of DcR3. In further experiments, luciferase assays, quantitative RT-PCR and immunoblot analyses were applied to study the regulation of DcR3 expression in RCC. Additionally, an ex vivo tissue slice culture technique combined with immunohistochemistry was used to study the regulation of DcR3 expression in human RCC specimens.

Results: Here, we show that DcR3 promotes adhesion, migration and invasiveness of RCC cells. The DcR3-dependent increase in cellular invasiveness is accompanied with an up-regulation of integrin alpha 4, matrixmetalloproteinase 7 and urokinase plasminogen activator (uPA). Further, we identified a signaling pathway regulating DcR3 expression in RCC. Using in vitro experiments as well as an ex vivo RCC tissue slice culture model, we demonstrate that expression of DcR3 is regulated in a PI3K/AKT-dependent manner involving the transcription factor nuclear factor of activated T-cells (NFAT).

Conclusions: Taken together, our results identify DcR3 as a key driver of tumor cell dissemination and suggest DcR3 as a promising target for rational therapy of RCC.

Keywords: DcR3, Renal cell carcinoma, AKT, NFAT, Metastasis

Background

Renal cancer accounts for 2.6 percent of all malignant diseases, with RCC (renal cell carcinoma) as the main type of tumor. Around 25% of patients diagnosed with RCC present with advanced disease, including metastasis of the primary tumor. With the onset of metastasis the median survival times for patients range between 10.9 and 29.9 months, depending on the drugs used [1,2]. One reason for the dismal prognosis is the poor response rate to many therapeutic approaches, such as chemotherapy or radiotherapy [3]. The development of (clear cell) renal cell carcinoma is closely linked to the loss of the VHL (von Hippel-Lindau) tumor-suppressor gene, encoding for a protein promoting the degradation of the transcriptional activators HIF1\textalpha (hypoxia-inducible factor) and HIF2\textalpha. With the loss of VHL, several hypoxia-inducible genes such as VEGF (vascular endothelial growth factor), TGF-\textalpha (transforming growth factor \textalpha), GLUT-1 (glucose transporter type 1) and carboanhydrase 9 are overexpressed and...
promote tumorigenesis [4-6]. Moreover, activation of the AKT-mTOR (mammalian target of rapamycin) pathway and deregulation of receptor tyrosine kinases contribute to the progression of RCC. These molecular aberrations are targeted by novel therapy strategies such as inhibitors of mTOR or tyrosine kinases [7]. Further, defects in the induction of apoptotic cell death, immune evasion mechanisms and a high metastatic potential are determinants of RCC. In these processes, the members of the TNF (tumor necrosis factor) superfamily play an important role. DcR3 (Decoy Receptor 3) is a soluble member of the TNFR (tumor necrosis factor receptor) superfamily [8]. DcR3 is capable to bind and neutralize CD95 ligand (CD95L, FasL, APO1L), TL1A (TNF-like molecule 1A) and LIGHT. By binding to these ligands DcR3 can inhibit apoptosis, induce angiogenesis and modulate immune cell functions [9-13]. Apart from its decoy function, DcR3 has been shown to induce macrophage differentiation as well as osteoclast formation [14,15]. Clinical data link DcR3 overexpression to different types of cancer, such as pancreatic, lung, hepatocellular and colorectal cancer [8,16-18]. In the tumor entities examined so far, overexpression of DcR3 correlates with higher grading, staging and metastasis [18-21]. In our previous work, we showed that DcR3 expression in RCC is associated with high grade and high stage tumors [19]. Moreover, DcR3 expression correlated with lymph node metastasis and distant metastasis. In addition, DcR3 negatively correlated with disease specific survival and progression free survival and qualified as an independent prognostic factor. In this study, we sought to explore the functional role of DcR3 in RCC. We demonstrate that DcR3 promotes adhesion, migration and invasiveness of RCC cells which is accompanied by an up-regulation of integrin alpha 4, matrixmetalloproteinase 7 and urokinase plasminogen activator (uPA). Further, we show that expression of DcR3 is regulated in a PI3K/AKT-dependent manner. Taken together, our results identify DcR3 as a key driver of tumor cell dissemination and suggest DcR3 as a promising target for rational therapy of RCC.

Results
DcR3 promotes migration of RCC cells
As our previous work demonstrates a clinical significance of DcR3 overexpression in RCC [19], we were interested in functionally characterizing DcR3 in RCC. To this end, we started to analyze several RCC cell lines for endogenous expression of DcR3 on mRNA and protein level by quantitative RT-PCR and immunoblot analysis. Human embryonic kidney derived 293-T cells were used as a control kidney cell line. Six out of eight RCC cell lines showed a moderate to high expression of DcR3 whereas 293T cells lacked DcR3 expression (Figure 1A; Additional file 1: Figure S1A). As DcR3 is a soluble protein, we additionally investigated its secretion by DcR3 expressing tumor cells. We detected DcR3 in the supernatant of all DcR3 expressing cell lines tested (Figure 1B).

Using these RCC cell lines, we aimed at characterizing the involvement of DcR3 in the regulation of cellular migration, invasion and adhesion. To analyze the effect of DcR3 expression on migratory ability we either down-regulated DcR3 using two different siRNAs (Figure 1C) or established transfectants stably overexpressing DcR3 (Figure 1D) and subjected the cells to scratch motility assays. By cytotoxicity analysis we confirmed that modulation of DcR3 expression was functional, as DcR3 overexpression protected cells from CD95L-induced apoptosis, while DcR3 knockdown sensitized cells to CD95L-induced apoptosis (Additional file 1: Figure S1B,C). The siRNA-mediated suppression of DcR3 expression significantly reduced the migratory ability of both cell lines tested (Figure 1E; Additional file 1: Figure S1D), whereas stable overexpression resulted in a strong increase of migration (Figure 1F; Additional file 1: Figure S1E). Consistently, addition of DcR3-containing supernatant rescued the migratory ability of cells with diminished DcR3 expression (Additional file 2: Figure S2A-D).

DcR3 increases invasiveness in RCC cells
Next, we tested whether an alteration in DcR3 expression affects the ability of RCC cells to invade the extracellular matrix. While knockdown of DcR3 substantially reduced the invasive capacity (Figure 2A), overexpression strongly enhanced the invasiveness in both cell lines tested (Figure 2B). In addition to the matrigel-coated invasion assay, we studied the invasiveness of RCC cells in a more complex extracellular matrix assay. Cells were grown to form spheroids, which were then implanted into a collagen type I gel-matrix. In line with the matrigel invasion results, overexpression of DcR3 significantly enhanced the invasive phenotype of both cell lines tested (Figure 2C).

Regulation of cellular adhesion to fibronectin by DcR3
As both migration and invasion are dynamic processes involving attachment and detachment to extracellular matrix proteins, we wondered whether the alteration of DcR3 expression might have effects on cellular adherence. To this end, we analyzed the ability of cells with modulated DcR3 expression to attach to cover glasses coated with fibronectin, which is present in RCC [22] and metastatic niches [23]. Interestingly, DcR3 knockdown decreased the ability to adhere to fibronectin (Figure 3A), while overexpression augmented adherence (Figure 3B). Based
on these results, we wondered whether DcR3 induces the expression of genes commonly associated with migration, invasion or adhesion. Interestingly we found a DcR3 dependent alteration of expression levels for ITGA4 (integrin alpha 4), MMP7 (matrixmetalloproteinase 7) and uPA (urokinase plasminogen activator) whereas expression levels of ITGB1 (integrin beta 1), MMP2 and MMP9 were unchanged (Figure 3C-F).

PI3K/AKT signaling regulates DcR3 expression in RCC
Both the expression data derived from human RCC samples [19] as well as the functional results obtained in the cell culture model indicate a key role of DcR3 in the process of invasion and metastasis. However, the mechanisms responsible for overexpression of DcR3 in RCC are not known. Since the PI3K/AKT pathway is deregulated in RCC [24], we investigated its involvement.
in the regulation of DcR3 expression. Treatment of RCC cell lines with both the PI3K-inhibitor LY294002 and the AKT-inhibitor IV (CAS-number: 681281-88-9) resulted in a strongly reduced DcR3 expression on both protein and mRNA level, indicating a regulation of DcR3 on the transcriptional level (Figure 4A). Correspondingly, overexpression of the constitutively active form of AKT led to an increased DcR3 expression (Figure 4B). The successful modulation of the PI3K/AKT pathway was further confirmed by analyzing the phosphorylation of AKT, its direct downstream target GSK-3β, the mTOR target P70S6K (Figure 4A,B) and by measuring the

Figure 2 DcR3 promotes invasiveness in RCC cells. (A,B) Boyden chamber assay of ACHN and 769-P cells transfected with two different DcR3-specific siRNAs or a non-specific siRNA (scram) (A) or stably overexpressing DcR3 or an empty vector control (neo) (B). Bars indicate the percentage of cellular invasion in correlation to control cells. Invaded cells were counted in five representative fields (mean ± SEM; n=3, **p<0.01, ***p<0.001; T-test). Representative images are shown (magnification: 200×). (C) Spheroid assay of ACHN and 769-P cells stably overexpressing DcR3 or an empty control vector (neo). Bars indicate the percentage of cell invasion in relation to cells stably transfected with an empty control vector (mean ± SEM; n=3; *p<0.05, T-test). Representative images are shown (magnification: 40×).
Figure 3 (See legend on next page.)
activity of the FOXO transcription factors (Additional file 3: Figure S3A,B). We further evaluated the role of GSK-3β and mTOR in the PI3K/AKT-dependent DcR3 regulation. Knockdown of GSK-3β, whose activity is negatively regulated by AKT, resulted in a moderate increase of DcR3 expression (Figure 4C). In contrast, the inhibition of mTOR using Everolimus had no impact on DcR3 expression (Figure 4D).

**NFATc1 mediates PI3K/AKT-dependent DcR3 expression**

GSK-3β and the family of FOXO transcription factors are both known to negatively regulate the transcription factor NFAT (nuclear factor of activated T-cells) [25]. Therefore, we investigated its role in the transcriptional regulation of DcR3. We treated the cells with Cyclosporine A or FK-506 (Tacrolimus) which are both immunosuppressants that inactivate calcineurin, the major activator of NFAT. Inhibition of calcineurin dramatically decreased the expression of DcR3 (Figure 5A), indicating a functional relevance of NFAT in DcR3 regulation. Accordingly, NFAT overexpression resulted in an increase in DcR3 expression level (Figure 5B). To demonstrate that modulation of the PI3K/AKT pathway affects NFAT expression, we performed nuclear and cytoplasmic fractionation and detected a shift of NFAT localization to the cytoplasm upon PI3K inhibition. A similar shift was detectable after Cyclosporine A treatment which served as a positive control. In contrast, treatment with Everolimus had no impact on NFAT localization, confirming an mTOR independent regulation (Figure 5C). In addition, the activity of NFAT was enhanced upon overexpression of a constitutively active form of AKT (Figure 5D).

**PI3K/AKT signaling regulates DcR3 expression in ex vivo cultured RCC tissue**

To confirm the importance of PI3K signaling for DcR3 expression in human RCC, we incubated freshly resected human RCC tissue slices with the PI3K-inhibitor LY294002. The inhibition of PI3K signaling significantly diminished DcR3 expression in all six examined cases, as assessed by immunohistochemistry (Figure 6A). These results were confirmed by immunoblot analyses of lysates generated in parallel (Additional file 3: Figure S3C). Furthermore, treatment of RCC tissue slices with LY294002 resulted in a reduced proliferation in four out of five cases as observed by Ki-67 staining. At the same time, apoptosis (assessed by immunohistochemical detection of cleaved caspase 3) was not induced to a significant extent by LY294002 (data not shown). To further examine a possible association of AKT activation levels and DcR3 expression, we subjected nine pairs of freshly obtained human RCC tissue and adjacent normal renal tissue to immunoblot analysis. Although a clear quantitative association of AKT phosphorylation and DcR3 expression levels was not evident, the majority of DcR3 positive tumor samples also showed elevated levels of active AKT compared to their corresponding normal tissue samples (Figure 6B).

**Discussion**

In our previous work we found a significant association of DcR3 expression levels and both lymph node and distant metastasis in a large collection of 560 human RCC samples [19]. Further, DcR3 expression was identified as a robust independent negative prognostic marker in patients with RCCs. In the present study we sought to elucidate the functional relevance of DcR3 for cellular migration, invasiveness and metastasis. Moreover, we investigated the mechanisms of how DcR3 expression is regulated in RCC.

Our results indicate that DcR3 is an important driver of adhesion, migration and invasiveness in RCC. Since these functional characteristics are hallmarks of the metastatic process the findings are in accordance with the clinical correlation of DcR3 expression and metastasis. Similar results obtained by studies of other types of cancer, such as breast and nasopharyngeal cancer, confirm the promoting effect on metastasis and invasiveness of DcR3 [26,27]. In addition to our functional observations, we found that DcR3 regulates the expression of proteins involved in migration and invasiveness. Modulation of DcR3 expression resulted specifically in transcriptional regulation of MMP-7, uPA and ITGA4, whereas the expression of other members of the matrixmetalloproteinase and integrin families was not altered. In a recent study of
Figure 4 DcR3 expression in RCC is PI3K/AKT-dependent. (A-D) Immunoblot analysis of whole-cell lysates and quantitative real-time-PCR assaying relative DcR3 mRNA expression of ACHN and 769-P cells 24 h after treatment with LY294002 (50 μM) or AKT-inhibitor IV (10 μM) (A); 48 h post transfection with constitutively active AKT (myrAKT) or an empty vector control (neo) (B); 48 h post transfection with GSK-3β-specific siRNAs or a non-specific siRNA (scram) (C); 24 h after treatment with Everolimus (1 μM) (D). Expression data were normalized to internal 18S rRNA expression (mean ± SEM; n=3; *p<0.05, **p<0.01, ***p<0.001; T-test).
ovarian cancer, DcR3 overexpression was shown to regulate a whole network of proteins. ITGA4, uPA and members of the MMP-family were positively regulated by DcR3 [28]. Additionally, DcR3 was shown to upregulate ITGA4 in macrophages [29]. These data provide additional evidence that DcR3 is involved in the induction of metastasis-associated genes. Interestingly, MMP7, uPA and ITGA4 have been shown to correlate with metastatic potential in RCC. ITGA4 is exclusively expressed in RCC in comparison to normal kidney tissue [30] and is associated with metastatic spread of RCC and other solid tumor entities by interacting with its ligands VCAM-1 (vascular cell adhesion protein 1) and fibronectin [31,32]. VCAM-1 and ICAM-1 (intercellular adhesion molecule 1) are other proteins that were shown to be upregulated upon DcR3 exposure on endothelial cells [33]. Since the interaction of ITGA4 with VCAM-1 is essential for the leukocyte adhesion cascade involving rolling, adhesion and transmigration through endothelial cells, DcR3 might enable cancer cells to mimic this process in order to form distant metastasis. Such
The mimicry effect has already been shown upon TNF-α (tumor necrosis factor α) stimulation in oral squamous cell carcinoma [34]. In addition, MMP-7 and uPA expression correlate with metastasis and poor survival rates in RCC [35,36]. The precise mechanism of DcR3 signaling remains unknown but could involve binding to the heparan sulfate proteoglycans syndecan-2 and CD44v3, both exerting downstream effects on Src (Rous sarcoma oncogene cellular homolog), Ras and consequently STAT3 (signal transducer and activator of transcription 3) signaling [37-40]. In our experiments we could confirm a role of STAT3 in DcR3 signaling (data not shown), whereas Src amongst other pathways such as PKC (protein kinase C)-, PI3K- and FAK (focal adhesion kinase)-dependent signaling is influenced by DcR3 in immune cell response [41]. Since both MMP-7 and ITGA4 are transcriptionally regulated by STAT3, Src/STAT3 signaling might explain the transcriptional regulation of MMP-7 and ITGA4 in the context of DcR3 [42,43].

The mechanisms of regulation of DcR3 expression in RCC have not yet been investigated. Our study demonstrates that DcR3 expression is regulated by a PI3K/AKT-dependent mechanism. In human pancreatic adenocarcinoma, DcR3 expression has been linked to PI3K/AKT signaling in cooperation with NFκB (nuclear factor κB), however, without further investigation of possible downstream mediators [44]. Another study linked Epstein-Barr virus transcription activator Rta to PI3K/AKT and NFκB signaling and increased DcR3 expression [45]. As AKT influences a whole network of proteins and interacts with different other pathways we evaluated the role of two major AKT downstream targets. Thereby we could...
of cancer cells, DcR3 might be a promising therapeutic pro-tumorigenic way as well as promoting metastasis inducing ligands, modulating the immune system in a promoting tumor progression by neutralizing apoptosis-members of the TNF and TNFR superfamilies.

similar mechanisms regulate the expression of different inhibition or SP-1 knockdown (data not shown). Thus, could also detect a decrease of DcR3 expression upon SP-1 bers is still missing [55]. In line with these observations we observed a decreased expression of DcR3 upon p65/RelA knockdown (data not shown). Since the PI3K/AKT pathway is able to positively regulate NFκB signaling [49], the PI3K/AKT/NFκB-mediated regulation of DcR3 might additionally be enhanced by the PI3K/AKT/NFκB axis. As the TNF superfamily shows structural similarities, one might assume similar mechanisms regarding regulation of expression. Interestingly, the soluble TNF superfamily members TRAIL (TNF-related apoptosis inducing ligand), CD95L, RANK-L (receptor activator of NFκB ligand) and TNF-α are upregulated by NFκB and SP-1 [50-54]. In contrast, the role of NFκB in the regulation of death receptors has not been examined in detail so far. SP-1 was reported to upregulate the expression of TRAIL-R2 (DR5; death receptor 5), while analysis of the other TNFR members is still missing [55]. In line with these observations we could also detect a decrease of DcR3 expression upon SP-1 inhibition or SP-1 knockdown (data not shown). Thus, similar mechanisms regulate the expression of different members of the TNF and TNFR superfamilies.

As DcR3 emerges as a multimodal molecule capable of promoting tumor progression by neutralizing apoptosis-inducing ligands, modulating the immune system in a pro-tumorigenic way as well as promoting metastasis of cancer cells, DcR3 might be a promising therapeutic target. The fact, that DcR3 is a secreted protein implies that DcR3 is capable of acting on its different target cells in a paracrine as well as a systemic manner, rendering it a powerful tool of the tumor to modulate the host system to form metastasis. On the other side, DcR3 is easily detectable in the blood serum of patients, opening up the possibility to use DcR3 as a biomarker for risk of metastasis and aggressive disease. Moreover, DcR3 expression could qualify as an indicator for the response and efficacy of a PI3K/AKT-targeting therapy. If the correlation between DcR3 expression and PI3K/AKT signaling activities proves to be stable in patients, the evaluation of DcR3 levels in urine or blood samples of patients could allow a selection of patients for treatment with PI3K/AKT-targeting therapeutics such as NVP-BEZ235 or SF1126 which are already in clinical trials for RCC and other solid tumor entities (NCT01453595; NCT00907205). SF1126 is a RGDS-conjugated LY294002 prodrug which is converted to the active compound LY294002 under physiologic conditions [56]. SF1126 is characterized by an increased solubility, by a prolonged half-life and by an improved delivery to the tumor [56]. It was recently evaluated in a phase I clinical trial in advanced solid tumors and B cell malignancies and has been proven to be well tolerated [57]. However, similarly to Ly294002 [58], SF1126 is likely to target signaling pathways other than PI3K/AKT, such as GSK3, mTOR and PI4K. So far the efficacy of a PI3K/AKT-targeting therapy in patients with RCC is not clear. DcR3 could serve as an easily measurable indicator for response, as DcR3 protein level should decrease upon PI3K/AKT inhibition. PI3K/AKT activation is a common event in cancer progression, either by loss of PTEN (phosphatase and tensin homolog) or activation of receptor tyrosine kinases by stimuli such as TGF-α or VEGF [59] the latter being highly upregulated in clear cell renal cancer. Consequently, PI3K/AKT-signaling is highly active in RCC and correlates with tumor burden and metastasis [60]. Thus, our findings suggest a new role of DcR3 in the context of rationally treating RCC patients. Our study warrants the further investigation of DcR3 in clinical settings.

Conclusions
This is the first study on the regulation and function of DcR3 in RCC. Our experiments identify DcR3 as a driver of adhesion, migration and invasiveness in RCC cells. These results confirm previous data demonstrating that DcR3 expression can be used as a biomarker for poor prognosis and risk of metastasis. Furthermore, we identified that DcR3 is regulated via a signaling axis involving PI3K/AKT and NFATc1. This newly discovered signaling pathway could be therapeutically exploited, since the subgroup of patients with DcR3 positive RCC might benefit from the inhibition of the drugable targets PI3K/AKT and NFATc1.

Methods
Reagents
Everolimus (#07741) was obtained from Sigma Aldrich (St. Gallen, Switzerland), LY294002 (#70920) was purchased from Cayman Chemicals Company (Ann Arbor, MI, USA) and AKT-inhibitor IV (#124011) was purchased from Calbiochem (Darmstadt, Germany). Cyclosporine A (#BML-A195) and CD95L (#ALX-522-001) were bought from Enzo life science (Loerrach, Germany). Tacrolimus (#10007965) was purchased from Biozol (Eching, Germany).
Cell culture
Human RCC cell lines 786-O, 769-P, ACHN, HTB-45 and 293-T were purchased from ATCC (Rockville, MD, USA). At ATCC the cell lines were authenticated by short tandem repeat profiling. KTCTL-2, KTCTL-26, KTCTL-30 and KTCTL-84 were obtained from the tumor cell bank of the German cancer research center (DKFZ; Heidelberg, Germany). All cell lines were maintained in RPMI1640 medium (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum, 1 mM glutamine, 25 mM glucose and 1% penicillin/streptomycin (Life Technologies, Germany). All data were analyzed anonymously. Written informed consent from the donors or the next of kin was obtained for use of these samples in research. Fresh human renal cell carcinoma tissue samples were obtained from the Tissue Bank of the Center for National Tumor Diseases (NCT, Heidelberg, Germany) directly after surgery and maintained in DMEM medium on ice. Tissue samples were cut into 300 μm thick slices by a Leica VT1200 S vibrating blade microtome (Leica, Wetzlar, Germany). Slices were then placed on porous filter membrane inserts in six-well plates and cultured in DMEM supplemented with penicillin (100 U/mL) and streptomycin (100 mg/mL) (Sigma Aldrich) in a conventional CO₂ incubator. After 24 hours, slices were treated with LY294002 for further 24 h. After treatment, tissue slices were fixed in 10% neutral-buffered formalin and embedded in paraffin. Four micrometer sections were stained with H&E or subjected to immunohistochemistry.

Paraffin-embedded tissue sections were dewaxed and rehydrated using xylene and a series of graded alcohols, followed by heat-induced antigen retrieval with a target retrieval solution (S2301, DakoCytomation, Glostrup, Denmark) in a pressure cooker for 15 min. For staining an automated staining system (Techmate 500, DakoCytomation) with avidin-biotin-complex peroxidase technique using aminoethylcarbazole for visualization and hematoxylin for counterstaining was used. Sections were incubated with primary antibody (anti-DcR3; BioLegend; London, United Kingdom; #333202; 6.25 μg/mL) for 30 min at room temperature and processed according to manufacturer’s protocol for the following kits: ChemMate Detection Kit (K5003, DakoCytomation), ChemMate Buffer Kit (K5006, DakoCytomation), Avidin/Biotin Blocking Kit (SP-2001, Vector Laboratories, Burlingame, CA, USA). For negative control of the staining procedure, primary antibody was omitted with all other experimental conditions kept constant.

Reporter gene assays
Cells were seeded into 12-well dishes and co-transfected with Renilla luciferase pRL-SV40P (Promega, Madison, WI, USA) and FHRE-Luc (Addgene Plasmid 1789) [64] or pGL3-NFAT luciferase (Addgene Plasmid 17870) [65]. 24 h after transfection cells were subjected to LY294002 or AKT-inhibitor IV treatment for further 24 h prior to the preparation of cell lysates. Both Firefly and Renilla luciferase activities were quantified using the dual-luciferase-reporter assay system (Promega), according to the manufacturer’s instructions.

Quantitative real-time PCR
Quantitative real-time PCR was performed as described previously [66]. Following primer pairs were used:

DcR3: 5’-CCACTACACGCAGTTCTGGA-3’ (forward)
Cells were rinsed with ice-cold PBS and lysed with lysis buffer (120 mM NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 0.5% Triton X-100) containing phenylmethylsulfonyl-flouride (1 mM), proteinase inhibitors (Roche, Mannheim, Germany, #1697498) and phosphatase inhibitors (5 mM EDTA, 0.5% Triton X-100) containing phenylmethylsulfonyl-flouride (1 mM), proteinase inhibitors (Roche, Mannheim, Germany, #1697498) and phosphatase inhibitors (25 mM NaF, 200 μM NaVO₃, 10 mM NaPP₄).

After 15 min incubation on ice, lysates were centrifuged at 16 000 g for 20 min. For cytoplasmic and nuclear fractions cells were harvested and processed with the Nuclear Extraction Kit (Active Motif, Rixensart, Belgium) according to manufacturer’s protocol. For protein isolation from human tissue, frozen tissue samples kindly provided by the Tissue Bank of the Center for National Tumor Diseases (NCT, Heidelberg, Germany) were suspended in 100 μl lysis buffer and shock frozen in liquid nitrogen. Thereafter 5 mm grinding balls were added. The tissue samples were homogenized by the use of a Mixer Mill MM 200 (Retsch, Haan, Germany) and centrifuged for 10 min at 16 000 g. For the isolation of proteins from supernatant, cells were incubated in serum-free medium. After 24–48 h the medium was harvested and centrifuged for 5 min at 1000 g. 200 μL of the supernatant were used for precipitation [67]. A Ponceau S-stained protein band was used for normalization. Total protein concentration was measured by Bradford-Assay (Bio-Rad, Munich, Germany). Following primary antibodies were used: anti-Dcr3 (BioLegend, #333202), anti-β-actin (Merck Millipore, Darmstadt, Germany, #mab1501), anti-AKT (Cell Signaling, Danvers, MA, USA, #9272), anti-phospho-AKT (Cell Signaling, #4058), anti-P70S6K (Cell Signaling, #9202), anti-phospho-P70S6K (Cell Signaling, #9206), anti-GSK-3β (Cell Signaling, #9315), anti-phospho-GSK-3β (Cell Signaling, #9336), anti-PARP (BD Pharmingen, San Diego, CA, USA, #556362), anti-Caspase 3 (Imgenex, San Diego, CA, USA, #IMG-144A), anti-NFATc1 (Abcam, Cambridge, MA, USA, #ab25916), and anti-ITGA4 (GeneTex, Irvine, CA, USA, #GTX61691).

**Immunoblot analysis**

Cells were rinsed with ice-cold PBS and lysed with lysis buffer (120 mM NaCl, 50 mM Tris–HCl (pH 8.0), 5 mM EDTA, 0.5% Triton X-100) containing phenylmethylsulfonyl-flouride (1 mM), proteinase inhibitors (Roche, Mannheim, Germany, #1697498) and phosphatase inhibitors (25 mM NaF, 200 μM NaVO₃, 10 mM NaPP₄). After 15 min incubation on ice, lysates were centrifuged at 16 000 g for 20 min. For cytoplasmic and nuclear fractions cells were harvested and processed with the Nuclear Extraction Kit (Active Motif, Rixensart, Belgium) according to manufacturer’s protocol. For protein isolation from human tissue, frozen tissue samples kindly provided by the Tissue Bank of the Center for National Tumor Diseases (NCT, Heidelberg, Germany) were suspended in 100 μl lysis buffer and shock frozen in liquid nitrogen. Thereafter 5 mm grinding balls were added. The tissue samples were homogenized by the use of a Mixer Mill MM 200 (Retsch, Haan, Germany) and centrifuged for 10 min at 16 000 g. For the isolation of proteins from supernatant, cells were incubated in serum-free medium. After 24–48 h the medium was harvested and centrifuged for 5 min at 1000 g. 200 μL of the supernatant were used for precipitation [67]. A Ponceau S-stained protein band was used for normalization. Total protein concentration was measured by Bradford-Assay (Bio-Rad, Munich, Germany). Following primary antibodies were used: anti-Dcr3 (BioLegend, #333202), anti-β-actin (Merck Millipore, Darmstadt, Germany, #mab1501), anti-AKT (Cell Signaling, Danvers, MA, USA, #9272), anti-phospho-AKT (Cell Signaling, #4058), anti-P70S6K (Cell Signaling, #9202), anti-phospho-P70S6K (Cell Signaling, #9206), anti-GSK-3β (Cell Signaling, #9315), anti-phospho-GSK-3β (Cell Signaling, #9336), anti-PARP (BD Pharmingen, San Diego, CA, USA, #556362), anti-Caspase 3 (Imgenex, San Diego, CA, USA, #IMG-144A), anti-NFATc1 (Abcam, Cambridge, MA, USA, #ab25916), and anti-ITGA4 (GeneTex, Irvine, CA, USA, #GTX61691).

**Scratch motility assay**

Cells (5 × 10⁴) were seeded into 12-well culture dishes. 24 h thereafter, a 100 μm scratch was placed within the confluent monolayer with a pipette tip. Cells were then placed into the incubation chamber of an Olympus IX81 microscope and cultivated at 37°C, 40% humidity and 5% CO₂. Throughout 24 h pictures were taken at intervals of 1–2 h with an Olympus U-CMAD3 camera by CellR software. Migratory activity was calculated with Image J software, based on the cell-free areas.

**Proliferation and clonogenicity assay**

For the assessment of proliferation, 2.5 × 10⁵ cells were seeded into 6-cm culture dishes and counted after 24 h, 48 h and 72 h using the trypan blue exclusion assay. For clonogenicity assays, 500 cells were seeded into 6-well culture dishes and incubated for seven days prior to crystal violet staining and colony counting.

**Boyden chamber assay**

The invasive capacity of cells was analyzed by the use of Matrigel™ coated chambers (BD Bioscience, Sparks, MD, USA) according to manufacturer’s protocol. Briefly, cells were starved for 24 h with serum free medium. After trypsinization, 10⁵ cells, suspended in 0.5 mL serum free medium, were seeded into the boyden chamber insert. 0.75 mL medium enriched with 20% FCS was added as a chemotaxtractant into the well. Cells were allowed to invade the Matrigel™ matrix for 24–48 h. Thereafter, transmigrated cells were fixed and stained with crystal violet.

**Spheroid invasion assay**

Cells (75 000–100 000) were resuspended in 20 μL medium. After 48 h, spheroids were formed and placed on the lid of a 100-mm Petri dish to form spheroids. 48 h later, spheroids were placed in cell culture dishes, coated with 2% sterile agar (Merck)/PBS (solidified) and filled with growth medium. 24 h later, spheroids were embedded into collagen gels. Collagen gels were made by mixing Vitrogen (97% collagen type I; Nutacon BV, Leimuiden, the Netherlands) with 10-fold
concentrated minimal essential medium (Life Technologies) and sterile 0.1 M sodium hydroxide, resulting in a final concentration of 2.4 mg/mL collagen. Collagen solution was distributed into 24-well plates (0.5 mL/well) which had previously been coated with 2% sterile agar (Merck)/PBS (solidified). After solidification gels were overlaid with growth medium. Cell invasion was monitored at intervals of 24 h by photographing spheroids with an inverted Olympus IMT2-RFA/340 phase contrast microscope.

Cytotoxicity assay
For acute cytotoxicity assays, 10⁴ cells were plated in 96-well plates, adhered for 24 h, and exposed to CD95L for 24 h. The percentage of surviving cells was assessed by staining with crystal violet [68]. Briefly, the supernatant was removed, and the cells were incubated in a 2% crystal violet solution for 20% methanol for 10 min. The plates were washed in running tap water and air-dried for 24 h. Crystal violet was solubilized by the addition of a 0.1 M sodium citrate buffer in 50% ethanol. The absorption was measured at 550 nm using a microplate reader (Bio-Rad).

Statistical methods
For all data, significant differences were identified using the unpaired 2-sided Student t test. Throughout, P values < 0.05 were considered significant and are indicated as follows: *P < 0.05, **P < 0.01, ***P < 0.001.

Additional files

Additional file 1: Figure S1. DcR3 expression in RCC. (A) Quantitative real-time-PCR assay of DcR3 mRNA expression levels. Expression data were normalized to internal 18S rRNA expression. (B) Cytotoxicity assay of ACHN and 769-P cells transfected with two different DcR3-specific siRNAs or a non-specific siRNA (scram). Cells were treated with CD95L (200 ng/µL) for 24 h prior to crystal violet staining (mean ± SEM; n=3; ***P<0.001; scram vs. DcR3-si1 and scram vs. DcR3-si2; T-test). (C) Cytotoxicity assay of CD95L sensitive LN18 glioblastoma cells stably overexpressing DcR3 or an empty vector control (neo). Cells were treated with CD95L (200 ng/µL) for 24 h prior to crystal violet staining (mean ± SEM; n=3; **P<0.01, ***P<0.001; T-test). (D) Scratch motility assay of ACHN and 769-P cells 24 h post transfection with myrAKT or an empty vector control (neo) (mean ± SEM; n=3; **P<0.01, ***P<0.001; T-test). (E) Scratch motility assay of ACHN and 769-P cells 24 h post transfection with LY294002 (100 µM). (F) Scratch motility assay of ACHN and 769-P cells 24 h post transfection with myrAKT or an empty vector control (neo) (mean ± SEM; T-test).

Additional file 2: Figure S2. DcR3 expression does not affect proliferation or clonogenicity in RCC. (A) Proliferation assay of ACHN and 769-P cells 24, 48 and 72 h after transfection with two different DcR3-specific siRNAs or a non-specific siRNA (scram). Cells were trypsinized and counted (mean ± SEM; n=3). (B) Proliferation assay of ACHN and 769-P cells stably overexpressing DcR3 or an empty vector control (neo) after 24, 48 and 72 h. Cells were trypsinized and counted (mean ± SEM; n=3). (C) Clonogenicity assay of ACHN and 769-P cells transfected with two different DcR3-specific siRNAs or a non-specific siRNA (scram). Cells were grown for 7–9 days, subsequently stained with crystal violet and colonies were counted (mean ± SEM; n=3).

Competing interests
The authors declared that they have no competing interests.

Authors’ contributions
DW carried out the experiments, participated in study conception and design, analyzed and interpreted the data, and was involved in drafting the manuscript. KET participated in study conception and design, analyzed and interpreted the data, and was involved in drafting the manuscript. SMG participated in study conception and design, and revised the manuscript for important intellectual content. AH participated in study conception and design, and revised the manuscript for important intellectual content. NW participated in study conception and design, and revised the manuscript for important intellectual content. WR participated in study conception and design, analyzed and interpreted the data, and was involved in drafting the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors thank all laboratory members for helpful suggestions and discussions. We further thank Prof. Dr. Volker Ellenrieder (Department of Gastroenterology, Endocrinology and Metabolism, University Hospital Giessen and Marburg) for providing plasmids and antibodies. Moreover we thank Lena Pawella, Michaela Bissinger and Kai Breuhahn (Institute of Pathology, University of Heidelberg) for introduction in the Olympus Imaging System and the Mixer Mill MM 200. We also thank Sarah Messner and Vanessa Vogel (Institute of Pathology, University of Heidelberg) for technical support. Furthermore we would like to thank Andrea Hain and the NCT for technical support and tissue supply. In addition we thank Anjana Rao, Michael Greenberg, Richard Roth and Jerry Crabtree for providing plasmids via Addgene. This study was supported by funds from German Cancer Aid (Deutsche Deutsche Krebshilfe; #109690; NW and WR), and Heinrich F.C. Behr Foundation (Stipend to DW).

Author details
1Molecular Tumor-Pathology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. 2Institute of Pathology, University of Heidelberg, Germany. 3Department of Urology, University of Frankfurt am Main, Frankfurt am Main 60590, Germany. 4Department of Urology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany. 5Department of Urology, University of Heidelberg, Heidelberg 69120, Germany.

Received: 8 July 2013 Accepted: 4 October 2013
Published: 10 October 2013

References
1. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005, 353:2477–2490.
2. Schmidinger M, Bellmunt J: Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010, 36:415–424.
3. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408–417.
4. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996, 93:10595–10599.
5. Tostain J, Li G, Gentili-Perrut A, Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. *Eur J Cancer* 2010, 46:3141–3148.

6. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. *Clin Cancer Res* 2007, 13:5858–763.

7. Cho D, Signoretto S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. *Clin Cancer Res* 2007, 13:5858–763.

8. Pitti RM, Masters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Widjaja W, Gurney AL, Hillian KJ, Cohen RL, Godard AD, Bottstein D, Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. *Nature* 1998, 396:659–703.

9. Roth W, Isenmann S, Nakamura M, Patten M, Wick W, Kleihue P, Bahr M, Oghahi H, Ashkenazi A, Weller M. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. *Cancer Res* 2001, 61:2759–2765.

10. Yang CR, Hsieh SL, Ho FM, Su WL, Lin WW. Soluble decoy receptor 3 induces angiogenesis by neutralization of T1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. *Cancer Res* 2004, 64:1122–1129.

11. Migone TS, Zhang J, Luo X, Zhaung L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Yu H, Ulrich S, Kanaan P, Carell J, Boyd E, Olsten HS, Gu H, Pucak L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P. T1A is a TNF-like ligand for DR3 and DR8/DR3 and functions as a T cell costimulator. *Immunity* 2002, 16:470–482.

12. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. *J Biol Chem* 1999, 274:13733–13736.

13. Shi G, Luo H, Wan X, Salcedo TW, Zhang J, Wu J. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. *Blood* 2002, 100:3279–3286.

14. Chang YC, Hsu TL, Lin HH, Chio CC, Chu AW, Chen NJ, Lin CH, Hsieh SL. Modulation of macrophage differentiation and activation by decoy receptor 3. *J Leukoc Biol* 2005, 77:486–494.

15. Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW. Decoy receptor 3 (DR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. *Cell Death Differ* 2004, 11(Suppl 1):S97–S107.

16. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Dallman A, oranges E, Allory Y, de la Motte C, Galloway SM, Liu Q, Austin CP, Caskey CT. Identification of pre-metastatic niche. *Clin Cancer Res* 2011, 17:12173–12182.

17. Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S, Kobayashi H, Hirao S, Mizuno T, Nakajima Y. The von Hippel-Lindau tumor suppressor protein and clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. *Eur J Cancer* 2010, 46:1049–1059.

18. Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Wu J. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. *Int J Cancer* 2003, 105:274–278.

19. Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA. Angiostatic action. *Cancer Res* 2004, 64:1122–1129.

20. Hartmann TN, Burger JA, Godec A, Fuji N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. *Cancer Res* 2005, 65:4462–4471.

21. Chu WH, Cheng H, Gershenson JD, Fan D, Fidler IL, Langley RG. Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. *Neoplasia* 2010, 12:173–182.

22. Yang CR, Hsieh SL, Ho FM, Lin WW. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule 1, VCAM-1, and IL-8 expression. *J Immunol* 2001, 174:1647–1656.

23. Song K, Zho F, Zhang HZ, Zhang JZ. Tumor necrosis factor-alpha enhanced fusions between oral squamous cell carcinoma cells and endothelial cells via VCAM-1/LFA-4 pathway. *Exp Cell Res* 2012, 318:1707–1715.

24. Miyata Y, Iwata T, Obha K, Senda S, Nishikido M, Kanetake H. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis. *Clin Cancer Res* 2005, 11:6998–7003.

25. Paule B, Deslandes E, Le Mouel P, Bastien L, Podgomiak MP, Alloy Y, de la Taille A, Menashi S, Calvo F, Mounah S. Identification of a novel biomarker signature associated with bone metastasis in patients with renal cell carcinoma. *Int J Biol Markers* 2010, 25:112–118.

26. Chang YC, Chan YH, Jackson DG, Hsieh SL, Ohgaki H, Ashkenazi A, Weller M. Soluble decoy receptor 3 is essential for induction of experimental autoimmune uveitis. *J Immunol* 2006, 176:173–180.

27. Bourguignon LY, Zhu H, Shao L, Chen WW. CD44 interaction with c-Src kinase promotes contactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. *J Biol Chem* 2001, 276:7327–7336.

28. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. *J Biol Chem* 2001, 276:48679–48692.
44. Chen PH, Yang CR: Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 2008, 181:8441–8449.

45. Li X, Wang X, Evers BM: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550–562.

46. Merseburger AS, Boni A, Kiesel M, Winterhalder M, Strasberg SM, Gossner A, Neiss A, Bacher M, Elsasser D: PI3K-Akt pathway inhibition in primary and metastatic renal cell carcinoma. Eur Urol 2006, 49:242–249.

47. Tsai ET, Falvo JV, Tsutsykaeva AV, Barczak AK, Reimold AM, Glimcher LH, Jackson A, McGlynn K: Cross-talk between NFAT and NF-kappaB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells. Curr Cancer Drug Targets 2011, 11:548–559.

48. Liu Q, Chen Y, Ruggeri PM, Molkentin JD: Interaction between NF-kappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 2012, 110:1077–1086.

49. Oeckinghaus A, Hayden MS, Ghosh S: Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011, 12:695–708.

50. Lawrence MC, Naziruddin B, Levy MF, Jackson A, McGlynn K: Calcium/nuclear factor of activated T cells and MAPK signaling induce TNF-alpha expression in pancreatic islet endocrine cells. J Biol Chem 2011, 286:1025–1036.

51. Lee HL, Ba C, Hwang HR, Qadir AS, Park HJ, Woo KM, Ryoo HM, Baek JH: High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-kappaB ligand in osteoblasts. Bone 2011, 49:242–249.

52. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Waterfield MD: Exploring the specificity of the PI3K family inhibitor LY294002. J Biol Chem 2007, 282:15474–15482.

53. Chen PH, Yang CR: Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 2008, 181:8441–8449.

54. Chen PH, Yang CR: Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 2008, 181:8441–8449.

55. Li X, Wang X, Evers BM: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550–562.

56. Merseburger AS, Boni A, Kiesel M, Winterhalder M, Strasberg SM, Gossner A, Neiss A, Bacher M, Elsasser D: PI3K-Akt pathway inhibition in primary and metastatic renal cell carcinoma. Eur Urol 2006, 49:242–249.

57. Tsai ET, Falvo JV, Tsutsykaeva AV, Barczak AK, Reimold AM, Glimcher LH, Jackson A, McGlynn K: Cross-talk between NFAT and NF-kappaB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells. Curr Cancer Drug Targets 2011, 11:548–559.

58. Liu Q, Chen Y, Ruggeri PM, Molkentin JD: Interaction between NF-kappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 2012, 110:1077–1086.

59. Oeckinghaus A, Hayden MS, Ghosh S: Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011, 12:695–708.

60. Lawrence MC, Naziruddin B, Levy MF, Jackson A, McGlynn K: Calcium/nuclear factor of activated T cells and MAPK signaling induce TNF-alpha expression in pancreatic islet endocrine cells. J Biol Chem 2011, 286:1025–1036.

61. Lee HL, Ba C, Hwang HR, Qadir AS, Park HJ, Woo KM, Ryoo HM, Baek JH: High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-kappaB ligand in osteoblasts. Bone 2011, 49:242–249.

62. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Waterfield MD: Exploring the specificity of the PI3K family inhibitor LY294002. J Biol Chem 2007, 282:15474–15482.

63. Chen PH, Yang CR: Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 2008, 181:8441–8449.

64. Chen PH, Yang CR: Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol 2008, 181:8441–8449.

65. Li X, Wang X, Evers BM: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550–562.

66. Merseburger AS, Boni A, Kiesel M, Winterhalder M, Strasberg SM, Gossner A, Neiss A, Bacher M, Elsasser D: PI3K-Akt pathway inhibition in primary and metastatic renal cell carcinoma. Eur Urol 2006, 49:242–249.

67. Tsai ET, Falvo JV, Tsutsykaeva AV, Barczak AK, Reimold AM, Glimcher LH, Jackson A, McGlynn K: Cross-talk between NFAT and NF-kappaB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells. Curr Cancer Drug Targets 2011, 11:548–559.

68. Liu Q, Chen Y, Ruggeri PM, Molkentin JD: Interaction between NF-kappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 2012, 110:1077–1086.

69. Oeckinghaus A, Hayden MS, Ghosh S: Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011, 12:695–708.

70. Lawrence MC, Naziruddin B, Levy MF, Jackson A, McGlynn K: Calcium/nuclear factor of activated T cells and MAPK signaling induce TNF-alpha expression in pancreatic islet endocrine cells. J Biol Chem 2011, 286:1025–1036.

71. Lee HL, Ba C, Hwang HR, Qadir AS, Park HJ, Woo KM, Ryoo HM, Baek JH: High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-kappaB ligand in osteoblasts. Bone 2011, 49:242–249.

72. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Waterfield MD: Exploring the specificity of the PI3K family inhibitor LY294002. J Biol Chem 2007, 282:15474–15482.